Sagimet Biosciences Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $9.85
- 52-Week Range
- $4.50 – $11.45
- Market Cap
- $727.27M
- P/E (TTM)
- —
- EPS (TTM)
- -1.18
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 2.61
- PEG Ratio
- —
- Return on Equity
- -29.50%
- Return on Assets
- -18.23%
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Profit Margin
- 0.00%
- Current Ratio
- 6.34
- Debt/Equity
- 0.01
- Total Debt
- $2.02M
- Free Cash Flow
- $-479.38K
- Revenue Growth
- —
- Earnings Growth
- —
- Enterprise Value
- $487.15M
Market Snapshot
About
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for metabolic dysfunction-associated steatohepatitis and other metabolic diseases. The company uses novel therapeutic approaches targeting fatty acid metabolism. Sagimet is advancing multiple drug candidates through clinical trials.